|
Preliminary results from patients with urothelial carcinoma (UC) in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody. |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Merck |
Consulting or Advisory Role - Amgen |
Speakers' Bureau - Bristol-Myers Squibb; Merck |
|
|
Employment - Tasman Oncology |
Stock and Other Ownership Interests - Tasman Oncology |
Research Funding - Tasman Oncology |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - AbbVie; Merck Serono |
Speakers' Bureau - Abbvie; Bristol-Myers Squibb; Ignyta |
Research Funding - AbbVie |
Travel, Accommodations, Expenses - AbbVie; Ignyta; Merck Sharp & Dohme |
|
|
Honoraria - AstraZeneca; Pfizer |
Consulting or Advisory Role - AstraZeneca; Pfizer |
|
|
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - BeiGene |
|
|
|
|
Stock and Other Ownership Interests - BeiGene |
|
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; GlaxoSmithKline; Novartis |
Consulting or Advisory Role - Amgen; Bionomics; Lilly; Novartis; Plexxikon |
Research Funding - Bionomics (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Roche (Inst) |